Clinical trials: Non-Small-Cell Lung
Advanced Stage Non-small Cell Lung Cancer
Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs
The purpose of this study is to closely examine tumor and blood samples from patients treated with nivolumab and ipilimumab in order to try to identify why some patients with lung cancers respond and why some patients do not.
- Trial name
- NCT02350764
- Testing
- nivolumab, pilimumab
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Carcinoma, Non-Small-Cell Lung
Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)
This is a Phase III, randomized, parallel-arm, placebo controlled, double blind, multicenter study assessing the efficacy and safety of durvalumab versus placebo following SoC chemotherapy in patients with completely resected…
- Trial name
- MERMAID-1 (NCT04385368)
- Testing
- Durvalumab + SoC chemotherapy
- Where
- 140 sites in United States, Argentina and 31 more
- Volunteers
- 89 people
- Sponsor
- AstraZeneca
Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer
A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
This randomized, multicenter, Phase III, open-label study will evaluate the efficacy and safety of alectinib versus crizotinib and to evaluate the pharmacokinetics of alectinib in asian participants with treatment-naive…
- Trial name
- NCT02838420
- Testing
- Alectinib, Crizotinib
- Where
- 19 sites in China, South Korea and 1 more
- Volunteers
- 187 people
- Sponsor
- Hoffmann-La Roche
Oncology, Melanoma
Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)
This is a Phase 1/2, first-in-human, open-label, dose escalation and dose-expansion study of E-602, administered alone and in combination with cemiplimab.
- Conditions
- Oncology, Melanoma, Ovarian Cancer, NSCLC
- Trial name
- GLIMMER-01 (NCT05259696)
- Testing
- E-602, Cemiplimab
- Where
- 13 sites in United States
- Volunteers
- 69 people
- Sponsor
- Palleon Pharmaceuticals, Inc.
Non-small Cell Lung Cancer (NSCLC)
A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations
The purpose of the study was to evaluate the progression free survival (PFS), based on independent radiologic review (IRR), of ASP8273 compared to erlotinib or gefitinib in patients with locally advanced, metastatic or…
- Trial name
- SOLAR (NCT02588261)
- Testing
- naquotinib mesilate, Erlotinib, Gefitinib
- Where
- 167 sites in United States, Australia and 21 more
- Volunteers
- 530 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Lung Cancer, Non-Small Cell, Non-Small-Cell Lung Cancer
Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage IIIB/IV Non-Small Cell Lung Cancer
The purpose of this study is to compare the efficacy and safety of a weekly regimen of two FDA approved drugs in combination versus one FDA approved drug in subjects with advanced non-small cell lung cancer who have received one…
- Trial name
- NCT00065182
- Testing
- Topotecan/Docetaxel combination, Docetaxel
- Where
- 85 sites in United States, Canada and 1 more
- Volunteers
- 399 people
- Sponsor
- GlaxoSmithKline
NSCLC
Phase II of Zactima Maintenance for Locally Advanced or Metastatic Non-small-cell Lung Carcinoma (NSCLC) Following Platinum-doublet Chemotherapy
This study is multicenter, randomized, double-blinded, placebo-controlled Phase II study comparing vandetanib (300mg daily) plus best supportive care (BSC) to placebo plus BSC as maintenance treatment in patients with locally…
- Trial name
- NCT00777179
- Testing
- Vandetanib
- Where
- 5 sites in South Korea
- Volunteers
- 117 people
- Sponsor
- Genzyme, a Sanofi Company
Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer
Docetaxel and Bortezomib in Treating Patients With Progressive or Recurrent Non-Small Cell Lung Cancer
This trial is studying two different schedules of docetaxel and bortezomib to compare how well they work in treating patients with progressive or recurrent non-small cell lung cancer.
- Conditions
- Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT00362882
- Testing
- docetaxel, bortezomib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- National Cancer Institute (NCI)
Non-Small Cell Lung Cancer
Ridaforolimus With Cetuximab: Adv Non-Small Cell Lung, Colorectal, Head & Neck Cancer
The main purpose of this study is to evaluate the best dose, safety and side effects of ridaforolimus when given with cetuximab for patients with head and neck, lung and colon cancer that has progressed after initial therapy.
- Trial name
- NCT01212627
- Testing
- Ridaforolimus
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Angela Taber MD
Dysphagia, Non-Small Cell Lung Cancer
Study to Evaluate Palifermin in the Reduction of Dysphagia in Patients With Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to determine if palifermin will reduce the incidence of dysphagia in patients receiving concurrent chemoradiotherapy followed by consolidation chemotherapy for treatment of unresectable stage III…
- Conditions
- Dysphagia, Non-Small Cell Lung Cancer, Lung Cancer
- Trial name
- NCT00094861
- Testing
- Palifermin, Radiotherapy, Paclitaxel
- Volunteers
- 100 people
- Sponsor
- Swedish Orphan Biovitrum
Non-Small Cell Lung Cancer
Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)
This Phase III study will be conducted to evaluate the efficacy and safety of YH25448 as first-line treatment in locally advanced or metastatic Non-small Cell Lung Cancer (NSCLC) patients with EGFR mutations
- Trial name
- NCT04248829
- Testing
- Lazertinib 240 mg/160 mg, Gefitinib 250 mg
- Where
- 80 sites in Australia, Greece and 11 more
- Volunteers
- 393 people
- Sponsor
- Yuhan Corporation
Lung Cancer
Pemetrexed &Oxaliplatin in Patients w Recurrent NSCLCa After Failure to Platinum Based Adjuvant Chem
The purpose of this study is: To find out if the chemotherapy treatment using Pemetrexed (Alimta) and Oxaliplatin (Eloxatin) given together will kill the cancer cells in the patient's body and shrink the size of their tumor.
- Trial name
- NCT00612677
- Testing
- Oxaliplatin, Pemetrexed
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Carcinoma, Non-Small-Cell Lung
Study Of CP-751,871 In Combination With Cisplatin And Gemcitabine In Chemotherapy-Naïve Patients With Advanced Non-Small Cell Lung Cancer
CP 751,871 is a fully human monoclonal antibody against the Insulin-Like Growth Factor 1 Receptor (IGF-1R). Preclinical and clinical data indicate that CP 751,871 augments the anti-tumor activity of chemotherapy.
- Trial name
- NCT00560573
- Testing
- CP-751,871, Cisplatin, Gemcitabine
- Where
- 4 sites in Belgium, Ireland and 1 more
- Volunteers
- 46 people
- Sponsor
- Pfizer
Carcinoma, Non Small Cell Lung
Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer
To assess the safety and efficacy of PF-00299804 in patients with advanced lung cancer.
- Trial name
- NCT00553254
- Testing
- PF-00299804
- Where
- 3 sites in South Korea
- Volunteers
- 55 people
- Sponsor
- Pfizer
Squamous Non-Small Cell Lung Cancer
A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]
This randomized, open-label study will evaluate the safety and efficacy of atezolizumab (MPDL3280A) in combination with carboplatin + paclitaxel or carboplatin + nab-paclitaxel compared with treatment with carboplatin +…
- Trial name
- NCT02367794
- Testing
- Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody, Carboplatin, Nab-Paclitaxel
- Where
- 242 sites in United States, Argentina and 24 more
- Volunteers
- 1,021 people
- Sponsor
- Hoffmann-La Roche
Neoplasms, Neoplasm Metastasis
A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread
The main objective of the dose-escalation parts of the trial is to determine the maximum tolerated dose (MTD), based on the frequency of patients experiencing dose-limiting toxicities (DLTs), and/or the recommended dose for…
- Conditions
- Neoplasms, Neoplasm Metastasis, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT03166631
- Testing
- BI 891065, BI 754091
- Where
- 3 sites in United States
- Volunteers
- 62 people
- Sponsor
- Boehringer Ingelheim
Non Small Cell Lung Cancer
A Study of HBI-8000 (Tucidinostat) With Pembrolizumab in Non-Small Cell Lung Cancer
A Phase 2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination with Pembrolizumab for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Trial name
- HBI-8000 (NCT05141357)
- Testing
- HBI-8000 in combination with pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 5 people
- Sponsor
- HUYABIO International, LLC.
Non-Small Cell Lung Cancer (NSCLC)
Vorinostat in Combination With Palliative Radiotherapy for Patients With Non-Small Cell Lung Cancer
This is a dose escalation study that will assess the safety of Vorinostat, a Histone Deacetylase (HDAC) inhibitor, in combination with palliative radiotherapy in patients with advanced or metastatic Non-Small Cell Lung Cancer…
- Trial name
- NCT00821951
- Testing
- Vorinostat, Radiotherapy
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Yale University
Non-small Cell Lung Cancer (NSCLC)
Calypso-based Deep Inspiration Breath Hold (DIBH) Radiation Treatments of Lung Cancer
The purpose of this study is to test the use of Calypso beacon implants as a way to determine where the lung tumor is located during radiation treatment.
- Trial name
- NCT02111681
- Testing
- Calypso Beacon Implantation
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lung Cancer
Real World Utilization and Outcomes With Dacomitinib First Line Treatment for EGFR Mutation-positive Advanced Non Small Cell Lung Cancer Among Asian Patients - A Multi Center Chart Review
This is a longitudinal, consecutive case-series, multi-center study with mixed prospective and retrospective data collection. Data will be collected from eligible adults with EGFR mutation-positive advanced non-small cell lung…
- Trial name
- NCT04609319
- Testing
- Dacomitinib
- Where
- 14 sites in China, India and 1 more
- Volunteers
- 307 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.